Meridian BioSciences
Needs attentionClinical-stage biotech developing an oral therapy for chronic inflammatory disease, currently in Phase II.
BiotechSeries CSwitzerlandInvested Dec 3, 2019Lead: Jerry
Next board meeting
Tue, August 25
in 4 weeks
Status rationale: A competing therapy received fast-track designation, and the Phase II timeline slipped a quarter on recruitment.Updated Jul 27, 2026
Context notes and commitments will appear here
Notes need a table the backend does not have yet, and an author needs a user account, which nothing in this system has.